Accustem Sciences (Accustem Sciences) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences Debt-to-Equity?

Accustem Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Accustem Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Accustem Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-2.62 Mil. Accustem Sciences's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Accustem Sciences's Debt-to-Equity or its related term are showing as below:

ACUT' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.76 Med: -0.14 Max: -0.03
Current: -0.02

During the past 2 years, the highest Debt-to-Equity Ratio of Accustem Sciences was -0.03. The lowest was -0.76. And the median was -0.14.

ACUT's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs ACUT: -0.02

Accustem Sciences Debt-to-Equity Historical Data

The historical data trend for Accustem Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences Debt-to-Equity Chart

Accustem Sciences Annual Data

Trend

Dec22

Dec23

Debt-to-Equity

-0.76

-0.03

Accustem Sciences Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial				-	-0.23	-0.06	-0.03	-

Competitive Comparison of Accustem Sciences's Debt-to-Equity

For the Biotechnology subindustry, Accustem Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Debt-to-Equity falls into.

Accustem Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Accustem Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.056	+	0)	/	-2.112
	=	-0.03

Accustem Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-2.62
	=	0.00

Accustem Sciences (OTCPK:ACUT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Accustem Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Accustem Sciences (Accustem Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001

Website

http://www.accustem.com

Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.